# A Study of LY2409021 in Participants With Type 2 Diabetes Mellitus

> **NCT02111096** · PHASE2 · TERMINATED · sponsor: **Eli Lilly and Company** · enrollment: 174 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** LY2409021
- **DRUG:** Sitagliptin
- **DRUG:** Placebo
- **DRUG:** Metformin
- **DRUG:** Sulfonylurea

## Key facts

- **NCT ID:** NCT02111096
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-04
- **Primary completion:** 2015-09
- **Final completion:** 2015-09
- **Target enrollment:** 174 (ACTUAL)
- **Why stopped:** The overall benefit-risk profile did not support continued development of LY2409021 for type 2 diabetes.
- **Last updated:** 2019-10-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02111096

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02111096, "A Study of LY2409021 in Participants With Type 2 Diabetes Mellitus". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02111096. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*